Division 3.2 Specific requirements for gene therapy medicinal productsF1F2 United Kingdom Original text. Later amendments are not shown. 3.2.1Introduction: finished product, active substance and starting materials 3.2.2Specific requirements Annotations Textual amendments F1 Substituted by Commission directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use (Text with EEA relevance). F2 Substituted by Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products (Text with EEA relevance). ← Division 3.1 Division 3.2 Division 3.2.1 →